|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
18
|
|
pubmed:dateCreated |
2006-8-14
|
|
pubmed:abstractText |
Infection by human cytomegalovirus (hCMV) remains a potent threat to susceptible people throughout the world. We have discovered a series of imidazolyl-pyrimidine compounds, which were found to be irreversible inhibitors of the hCMV UL70 primase based on results from radiolabeling and SAR studies. Two promising analogs are described that rival ganciclovir and cidofovir in antiviral potency and possess improved cytotoxicity profiles.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Sep
|
|
pubmed:issn |
0960-894X
|
|
pubmed:author |
pubmed-author:AdrianJJ,
pubmed-author:ChewAA,
pubmed-author:CushingT DTD,
pubmed-author:DiMaioHH,
pubmed-author:DoughanBB,
pubmed-author:FlygareJJ,
pubmed-author:JaenJJ,
pubmed-author:LiangLL,
pubmed-author:MayorgaVV,
pubmed-author:MellorDD,
pubmed-author:MiaoSS,
pubmed-author:PetersonM GMG,
pubmed-author:PowersJ PJP,
pubmed-author:SpectorFF,
pubmed-author:SteinCC,
pubmed-author:WrightMM,
pubmed-author:XuDD,
pubmed-author:YuAA
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
15
|
|
pubmed:volume |
16
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
4879-83
|
|
pubmed:meshHeading |
|
|
pubmed:year |
2006
|
|
pubmed:articleTitle |
Discovery of a novel series of inhibitors of human cytomegalovirus primase.
|
|
pubmed:affiliation |
Amgen Inc., 1120 Veterans Boulevard, South San Francisco, CA 94080, USA. tcushing@amgen.com
|
|
pubmed:publicationType |
Journal Article
|
